Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non–muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial

Overview of attention for article published in European Urology, December 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (89th percentile)
Good Attention Score compared to outputs of the same age and source (68th percentile)

Mentioned by

twitter: 18 X users

guideline: 1 clinical guideline source

Readers on

mendeley: 27 Mendeley

So far, Altmetric has seen 28 X posts from 18 X users, with an upper bound of 120,091 followers.

RT @UrogerliMD: @eugene_pietzak @MarkTysonMD Same goes for BOND-003. The reasoning being serum anti-adenovirus titers can be generated due…

@eugene_pietzak @MarkTysonMD Same goes for BOND-003. The reasoning being serum anti-adenovirus titers can be generated due to treatment https://t.co/GSLhaxpSH8 @APMitra @VikramNarayan Would be a fascinating question to work out in real practice

March 2022 Issue Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non–muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial https://t.co/8AwGPyz9rU https://t.co/JXV2xU…

RT @EUplatinum: Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non–muscle-in…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 24 additional X posts.